Cellectis SA (STU:ZVAA)
€ 1.58 0.1 (6.76%) Market Cap: 158.14 Mil Enterprise Value: 5.54 Mil PE Ratio: 0 PB Ratio: 1.45 GF Score: 69/100

Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 05:00PM GMT
Release Date Price: €2.26 (-5.04%)
Matthew (Trades, Portfolio)atorre
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone, and thank you for joining us for Day 4 of the Goldman Sachs Healthcare Conference. We're really pleased to have Cellectis here. And with us, we have Bing Wang, CFO. So just to get started. So Cellectis is a clinical-stage biotech company using its platform to develop cell therapies.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot